Country: Canada
Language: English
Source: Health Canada
INCOBOTULINUMTOXINA
MERZ PHARMACEUTICALS GMBH
M03AX01
BOTULINUM TOXIN
100UNIT
POWDER FOR SOLUTION
INCOBOTULINUMTOXINA 100UNIT
INTRAMUSCULAR
1/2/3/6 VIALS
Prescription
OTHER MISCELLANEOUS THERAPEUTIC AGENTS
Active ingredient group (AIG) number: 0153613001; AHFS:
APPROVED
2012-04-12
_XEOMIN COSMETIC_ _®_ _ (incobotulinumtoxinA) - Product Monograph _ _Page 1 of 38_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR XEOMIN COSMETIC ® incobotulinumtoxinA Clostridium Botulinum Neurotoxin Type A (150 kD), free from complexing proteins Powder for solution for injection 100 units per vial Intramuscular injection Pharmaceutical Standard: House Muscle relaxant, peripherally acting agent Manufactured by: Merz Pharmaceuticals GmbH Eckenheimer Landstraße 100 60318 Frankfurt/Main Germany http://www.merz.com/company/merz_pharmaceuticals/ Imported and distributed by: Merz Pharma Canada Ltd. 5515 North Service Road, Ste 202 Burlington, ON L7L 6G4 Date of Initial Authorization: April 12, 2012 Date of Revision: October 3, 2023 Submission Control Number: 274814 _ _ _XEOMIN COSMETIC_ _®_ _ (incobotulinumtoxinA) - Product Monograph _ _Page 2 of 38_ RECENT MAJOR LABEL CHANGES 2. CONTRAINDICATIONS 04/2023 3. SERIOUS WARNINGS AND PRECAUTIONS BOX 01/2023 4. DOSAGE AND ADMINISTRATION, 4.1 DOSING CONSIDERATIONS 01/2023 7. WARNINGS AND PRECAUTIONS, DRIVING AND OPERATING MACHINERY 01/2023 TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES ............................................................................................. 2 TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 4 1. INDICATIONS ................................................................................................................ 4 1.1 Pediatrics ..................................................................................................................... 4 1.2 Geriatrics ..................................................................................................................... 4 2. CONTRAINDICATIONS .................................................................................................. 4 3. SERIOUS WARNINGS AND P Read the complete document